Compare Kroger Co (KR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Viatris Inc — how do they compare? Kroger Co trades at $57.31 (market cap $35.75B), while Viatris Inc trades at $17.37 (market cap $19.79B). The key difference: Kroger Co is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| KR | VTRS | |
|---|---|---|
Market Cap | $35.75B | $19.79B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $17.39 |
52-Week Low | $55.53 | $8.74 |
Enterprise Value | $55.85B | $32.00B |
Dividend Yield | 2.47% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $58.39, down 0.73% on the day, with a bearish technical signal and mixed earnings history. The company maintains stable revenue near $147 billion (2025) and recently announced a $1.65 billion acquisition of Giant Eagle (Reuters, July 1, 2026). Cash flow from operations remains strong at $5.79 billion, though net income margin is thin at 0.71%.
Outlook: KR offers value with low P/S (0.25) and dividend yield, but faces margin pressure and integration risks from acquisitions. Analyst consensus is bullish with a $68.63 price target, though technical weakness and competitive threats warrant caution for near-term volatility.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
